Therapeutic guidance of tumor mutation burden on immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and comprehensive meta-analysis
{{output}}
Background: Tumor mutation burden (TMB) remains a promising but ambiguous predictive biomarker for the efficacy of immune checkpoint inhibitors (ICIs). We investigated the predictive value of TMB in patients with advanced non-sma... ...
